+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Lupus Nephritis Global Clinical Trials Review, H2, 2019

  • ID: 4655664
  • Clinical Trials
  • December 2019
  • Region: Global
  • 173 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Biogen Inc
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Immune Tolerance Network
  • Johnson & Johnson
  • MORE
Lupus Nephritis Global Clinical Trials Review, H2, 2019

Summary

The clinical trial report, “Lupus Nephritis Global Clinical Trials Review, H2, 2019“ provides an overview of Lupus Nephritis clinical trials scenario. This report provides top line data relating to the clinical trials on Lupus Nephritis . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Biogen Inc
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Immune Tolerance Network
  • Johnson & Johnson
  • MORE
  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Lupus Nephritis to Immunology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Lupus Nephritis to Immunology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Lupus Nephritis Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Lupus Nephritis
  • Nov 11, 2019: Genentech’s Gazyva (obinutuzumab), in Combination With Standard of Care, More Than Doubles the Percentage of Lupus Nephritis Patients Achieving Complete Renal Response, Compared To Standard of Care Alone
  • Nov 08, 2019: Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week
  • Nov 06, 2019: Equillium to present new data and insights on the CD6-ALCAM pathway in Lupus Nephritis at ACR 2019
  • Oct 16, 2019: Aurinia reports last patient study visit in Aurora phase 3 lupus nephritis study and provides update on ATM facility
  • Oct 11, 2019: Apellis to present data on APL-2 in complement 3 Glomerulopathy at ASN Kidney Week 2019
  • Oct 01, 2019: Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update
  • Sep 25, 2019: Omeros announces publication of study showing that inhibition of MASP-2, the key enzyme of the complement system’s Lectin Pathway, protects against renal injury caused by Proteinuria
  • Sep 19, 2019: Roche receives FDA breakthrough status for lupus nephritis drug
  • Clinical Trial Profile Snapshots
Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About the Author
  • Contact Us
  • Source
List of Tables
  • Lupus Nephritis Therapeutics, Global, Clinical Trials by Region, 2019*
  • Lupus Nephritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
  • Lupus Nephritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Europe, Top Five Countries, 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, North America, Top Countries, 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019*
  • Proportion of Lupus Nephritis to Immunology Clinical Trials, G7 Countries (%), 2019*
  • Lupus Nephritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
  • Lupus Nephritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
  • Proportion of Lupus Nephritis to Immunology Clinical Trials, E7 Countries (%), 2019*
  • Lupus Nephritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
  • Lupus Nephritis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
  • Lupus Nephritis Therapeutics, Global, Clinical Trials by Phase, 2019*
  • Lupus Nephritis Therapeutics, Global, Clinical Trials In Progress by Phase 2019*
  • Lupus Nephritis Therapeutics, Global, Clinical Trials by Trial Status, 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Global, by End Point Status, 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Lupus Nephritis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
List of Figures
  • Lupus Nephritis Therapeutics, Global, Clinical Trials by Region (%), 2019*
  • Lupus Nephritis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
  • Lupus Nephritis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, North America, Top Countries (%), 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019*
  • Proportion of Lupus Nephritis to Immunology Clinical Trials, G7 Countries (%), 2019*
  • Lupus Nephritis Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
  • Lupus Nephritis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
  • Proportion of Lupus Nephritis to Immunology Clinical Trials, E7 Countries (%), 2019*
  • Lupus Nephritis Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
  • Lupus Nephritis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
  • Lupus Nephritis Therapeutics, Global, Clinical Trials by Phase (%), 2019*
  • Lupus Nephritis Therapeutics, Global, Clinical Trials In Progress by Phase, 2019*
  • Lupus Nephritis Therapeutics, Global, Clinical Trials by Trial Status, 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Global, by End Point Status, 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
  • Lupus Nephritis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
  • Lupus Nephritis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
  • Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • F. Hoffmann-La Roche Ltd
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Novartis AG
  • Aurinia Pharmaceuticals Inc
  • C. H. Boehringer Sohn AG & Co KG
  • Biogen Inc
  • Immune Tolerance Network
  • Johnson & Johnson
  • Pamplona Capital Management LLP
Note: Product cover images may vary from those shown
Adroll
adroll